JILLIAN GREER: Open Payments
NPI 1063042513 · HOBART, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,620 in 202 payments from 23 companies in 2025. Trend: 2023 $4,172 · 2024 $3,886 · 2025 $3,620
Food & beverage: $3,620
| Company | Payments | Amount |
|---|---|---|
| RECORDATI_RARE_DISEASES_INC. | 34 | $482 |
| Ascensia Diabetes Care Us Inc. | 20 | $329 |
| Amneal Pharmaceuticals LLC | 20 | $312 |
| ABBVIE INC. | 15 | $285 |
| Medtronic, Inc. | 7 | $282 |
| Madrigal Pharmaceuticals | 8 | $280 |
| Lilly USA, LLC | 16 | $279 |
| Novo Nordisk Inc | 16 | $237 |
| Amgen Inc. | 12 | $218 |
| Xeris Pharmaceuticals, Inc. | 17 | $212 |
Products named: ISTURISA, UNITHROID, INPEN SMART INSULIN DELIVERY SYSTEM, REZDIFFRA, MOUNJARO, SYNTHROID, Korlym, JARDIANCE.
Industry payments across IN — which companies pay providers there.
